Anti-CD30 Antibodies for Hodgkin lymphoma.
Treatment of refractory or relapsed classical Hodgkin lymphoma (HL) remains challenging, but targeted immunotherapy has recently emerged as a potential treatment option for these patients. Although first-generation monoclonal anti-CD30 antibodies proved disappointing, current efforts to modify anti-CD30 antibodies to improve binding of effector cells and enhance activity appears more promising, as does the development of novel antibody-drug conjugates (ADCs). ADCs offer the potential to deliver potent therapies with minimal toxicity. One highly active ADC, brentuximab vedotin (SGN-35), combines an anti-CD30 monoclonal antibody and the antitubulin agent monomethyl auristatin E. Initial phase 1 studies of brentuximab vedotin showed a 52% overall response rate in relapsed HL, with minimal toxicity. This article highlights the development of anti-CD30 antibodies and ADCs for relapsed or refractory classical HL.
Foyil
Kelley V
KV
Washington University School of Medicine, Siteman Cancer Center, 660 South Euclid, Box 8056, St. Louis, MO 63110, USA.
Bartlett
Nancy L
NL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007167:Immunotherapy; D017730:Ki-1 Antigen / Q000276:immunology*; D009842:Oligopeptides / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D009842:Oligopeptides; D000079963:Brentuximab Vedotin; C495575:monomethyl auristatin E
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8444-8
17488826
J Clin Invest. 1997 Sep 1;100(5):1059-70
9276722
J Clin Oncol. 2007 Jul 1;25(19):2764-9
17515574
Leukemia. 2005 Sep;19(9):1648-55
16049514
Int J Cancer. 1995 Feb 8;60(4):539-44
7530238
Br J Haematol. 2008 Jul;142(1):69-73
18477046
Blood. 2003 Nov 15;102(10):3737-42
12881320
Blood. 2009 Jun 4;113(23):5920-6
19188663
Hematology Am Soc Hematol Educ Program. 2009;:507-19
20008236
Cancer. 2003 Jul 15;98(2):310-4
12872350
Cancer. 2002 Jan 1;94(1):1-5
11815953
Cancer Res. 2002 Jul 1;62(13):3736-42
12097283
Blood. 2008 Feb 15;111(4):1848-54
18079362
Lancet. 1992 May 16;339(8803):1195-6
1349939
Nat Biotechnol. 2003 Jul;21(7):778-84
12778055
N Engl J Med. 2010 Mar 11;362(10):875-85
20220182
Blood. 2009 Mar 19;113(12):2765-3775
19096012
Blood. 1998 Jan 15;91(2):399-405
9427692
Bioconjug Chem. 2002 Jul-Aug;13(4):855-69
12121142
Cancer Res. 2001 Dec 15;61(24):8737-42
11751393
Clin Cancer Res. 2002 Jun;8(6):1779-86
12060617
J Immunol Methods. 2005 Nov 30;306(1-2):151-60
16219319
Blood. 1997 Aug 1;90(3):1109-14
9242542
Br J Haematol. 2009 Jul;146(2):171-9
19466965
Cancer Res. 2005 Sep 15;65(18):8331-8
16166310
Blood. 2008 Apr 1;111(7):3830-7
18230757
Clin Cancer Res. 2004 Oct 15;10(20):7063-70
15501986
Lab Invest. 2000 Jul;80(7):1111-9
10908157
Ann Oncol. 2007 Jun;18(6):1071-9
17426059
Clin Cancer Res. 2009 May 15;15(10):3376-83
19401346
J Clin Oncol. 2005 Jul 20;23(21):4669-78
16034043
Protein Eng Des Sel. 2006 Jul;19(7):299-307
16644914
Bioconjug Chem. 2005 Sep-Oct;16(5):1282-90
16173809